Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (HKG:2566)

Market Cap	1.86B +5.7%
Revenue (ttm)	1.43B -1.6%
Net Income	135.25M -4.1%
EPS	0.60 -15.5%
Shares Out	241.52M
PE Ratio	12.90
Forward PE	n/a
Dividend	0.06 (0.78%)
Ex-Dividend Date	n/a

Volume	600
Average Volume	46,600
Open	7.69
Previous Close	7.69
Day's Range	7.69 - 7.69
52-Week Range	5.36 - 16.29
Beta	n/a
RSI	27.07
Earnings Date	Mar 26, 2026

About HKG:2566

Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research, development, production, and sale of biopharmaceutical products and medical devices. The company offers Guyoudao, a recombinant human bone morphogenetic protein-2 bone repair product; Jilifen, a human granulocyte colony-stimulating factor injection for neutropenia; Jijufen, a human interleukin-11 injection for chemotherapy-induced thrombocytopenia; and Jiouting, a palonosetron hydrochloride injection for nausea and vomiting induced by rad...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 1,629
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2566

Financial Performance

In 2024, HKG:2566's revenue was 1.37 billion, an increase of 6.35% compared to the previous year's 1.29 billion. Earnings were 138.60 million, an increase of 15.72%.

Financial numbers in CNY